HELICOBACTER PYLORI - IgM (ELISA)

Bacterial/ Viral

Report in 120Hrs

At Home

No Fasting Required

Details

Detects the presence of IgM antibodies against H. pylori bacteria in the blood using the ELISA (Enzyme-Linked Immunosorbent Assay) method

₹2,633₹4,388

40% OFF

HELICOBACTER PYLORI - IgM (ELISA) - Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Purpose: This test detects IgM antibodies against Helicobacter pylori (H. pylori), a bacterium that colonizes the gastric mucosa. IgM antibodies are produced during the acute or early phase of H. pylori infection, making this test valuable for identifying recent or acute infections.
- Primary Indications for Testing: Evaluation of acute upper gastrointestinal symptoms including epigastric pain, nausea, vomiting, and dyspepsia
- Diagnosis of acute H. pylori infection in symptomatic patients
- Differentiation of acute infection from chronic/past infection (IgM positive suggests recent exposure)
- Investigation of suspected acute gastritis or peptic ulcer disease
- Assessment in patients with family history of gastric cancer or H. pylori-related disease
- Timing of Testing: IgM antibodies typically appear within the first 2-4 weeks of acute infection and may persist for 2-3 months. This test is most useful in the early/acute phase of infection before IgG antibodies become predominant.
Section 2: Normal Range
- Reference Range Values:
- Negative/Normal: < 0.9 AU/mL (Arbitrary Units) or negative - Indicates no detectable IgM antibodies against H. pylori; suggests no recent acute infection
- Borderline/Equivocal: 0.9 - 1.1 AU/mL - Results in gray zone requiring repeat testing in 1-2 weeks or confirmatory tests
- Positive: > 1.1 AU/mL - Indicates detectable IgM antibodies; suggests recent or acute H. pylori infection
- Units of Measurement: AU/mL (Arbitrary Units per milliliter) or OD (Optical Density) values depending on laboratory methodology. Some laboratories report as optical density ratios or as simple positive/negative results.
- Clinical Interpretation:
- Normal Result: Absence of IgM antibodies suggests either no H. pylori infection or chronic/past infection where IgM has waned and only IgG remains
- Abnormal Result: Presence of IgM antibodies indicates acute or recent H. pylori infection, typically within the preceding 2-4 weeks to 2-3 months
Section 3: Interpretation
- Positive IgM Result (> 1.1 AU/mL):
- Indicates recent or acute H. pylori infection, typically within the previous 2-4 weeks
- Suggests patient is in the early phase of infection when primary antibody response is occurring
- May be associated with acute gastritis, acute peptic ulcer formation, or beginning mucosal inflammation
- Clinical significance: Usually warrants antimicrobial therapy to eradicate the infection before chronic complications develop
- Negative IgM Result (< 0.9 AU/mL):
- Rules out acute H. pylori infection in most cases
- May indicate chronic or past infection (IgG positive, IgM negative) or no H. pylori exposure
- If clinical suspicion for acute infection remains high, other diagnostic methods should be considered (rapid urease test, PCR, stool antigen)
- Borderline/Equivocal Result (0.9-1.1 AU/mL):
- Requires repeat testing after 1-2 weeks to allow antibody levels to rise into clearly positive range
- Consider confirmatory testing with IgG, urea breath test, or stool antigen detection
- Factors Affecting Results:
- Timing of test relative to infection onset - IgM appears 2-4 weeks after infection begins
- Individual immune response variation - Some patients mount weaker antibody responses
- Immunocompromised states - May result in absent or weak antibody response
- Recent antimicrobial use - May suppress bacterial load and reduce antibody production
- Prior H. pylori exposure - Past infection may provide some residual IgM but typically becomes negative
- Clinical Significance Patterns:
- IgM positive + IgG negative: Very recent acute infection (within 2-4 weeks)
- IgM positive + IgG positive: Acute infection progressing to chronic phase
- IgM negative + IgG positive: Chronic or past infection
- IgM negative + IgG negative: No H. pylori infection or very early infection before antibody production
Section 4: Associated Organs
- Primary Organ System: Gastrointestinal tract, specifically the stomach (gastric mucosa and antrum). H. pylori is a gram-negative microaerophilic bacterium that colonizes the gastric epithelium.
- Commonly Associated Medical Conditions:
- Acute Gastritis - Acute inflammation of the gastric mucosa presenting with epigastric pain, nausea, and vomiting
- Peptic Ulcer Disease - Both gastric and duodenal ulcers; acute IgM response may occur during acute ulcer formation or reactivation
- Chronic Gastritis - Progressive inflammatory condition; acute IgM phase can transition to chronic IgG-mediated disease
- Gastric Adenocarcinoma - H. pylori is classified as a Group 1 carcinogen; chronic infection increases risk
- MALT Lymphoma (Mucosa-Associated Lymphoid Tissue Lymphoma) - H. pylori is strongly associated with development of gastric MALT lymphoma
- Functional Dyspepsia - Chronic symptoms may result from H. pylori infection and ongoing mucosal inflammation
- ITP (Immune Thrombocytopenic Purpura) - Autoimmune thrombocytopenia associated with H. pylori infection in some patients
- Complications Associated with Acute Infection:
- Acute bleeding from gastric ulceration - May lead to hematemesis or melena
- Perforation - Acute ulcer perforation leading to peritonitis (rare but serious complication)
- Severe acute gastritis with significant mucosal damage and inflammation
- Progression to chronic disease if untreated - May lead to atrophic gastritis, intestinal metaplasia, and increased cancer risk
- Long-term Risks of Untreated Infection:
- Development of chronic atrophic gastritis with loss of normal gastric gland architecture
- Intestinal metaplasia - Pre-malignant change in gastric mucosa
- Dysplasia and progression to gastric adenocarcinoma - Significantly increased lifetime risk
- Gastric MALT lymphoma development - Can occur years after initial infection
Section 5: Follow-up Tests
- Recommended Follow-up Tests if IgM Positive:
- H. pylori IgG (ELISA) - Confirms chronic infection status and helps stage infection chronicity. IgG presence with IgM indicates progression to chronic phase.
- Urea Breath Test (UBT) - Non-invasive gold standard for active H. pylori infection; confirms active bacterial colonization
- H. pylori Stool Antigen Test - Detects bacterial antigen in feces; useful for confirming active infection
- Rapid Urease Test (RUT) - Performed during upper endoscopy; uses gastric biopsy samples
- H. pylori PCR - Molecular test with high specificity; useful in difficult-to-diagnose cases
- Upper GI Endoscopy - Indicated if symptoms persist or if IgM positive result to visualize gastric/duodenal pathology and obtain biopsies
- Tests for Borderline/Equivocal Results:
- Repeat H. pylori IgM ELISA in 1-2 weeks - Allow antibody levels to rise into clearly positive range
- H. pylori IgG to determine infection stage
- Consider more sensitive diagnostic methods (UBT, stool antigen, PCR) for confirmation
- Post-Treatment Monitoring:
- Follow-up testing at 4-6 weeks after completion of eradication therapy to confirm bacterial elimination
- IgM will gradually decline and become negative after successful eradication
- IgG may persist for years even after successful eradication, so it is not useful for post-treatment assessment
- Use Urea Breath Test or stool antigen testing post-treatment (preferred methods)
- Monitoring Frequency for Ongoing Management:
- During acute phase: Close clinical monitoring with symptom assessment
- Weekly evaluations if severe symptoms or complications suspected
- Post-treatment: Long-term follow-up at 6-12 months to assess for symptom recurrence or reinfection
- Complementary Diagnostic Tests:
- Complete Blood Count (CBC) - May show anemia if bleeding complications occur
- Serum pepsinogen levels - Marker of gastric mucosal atrophy; elevated ratios may indicate advanced disease
- Gastrin levels - Elevated in cases with achlorhydria or severe atrophic gastritis
Section 6: Fasting Required?
- Fasting Requirement: No
- Fasting is NOT required for H. pylori IgM ELISA testing. This serology test can be performed at any time of day without dietary restrictions.
- Sample Collection Requirements:
- Specimen type: Serum (blood sample)
- Collection method: Venipuncture using a serum separator tube (SST) or plain glass tube
- Volume: Typically 5-10 mL of blood
- Serum must be separated from cells within 1 hour of collection
- Storage: Refrigerate at 2-8°C if not testing immediately; can be frozen at -20°C for longer storage
- Medications to Avoid:
- H. pylori IgM ELISA is a serologic test and is NOT affected by routine medications
- However, certain medications may affect infection detection indirectly:
- Recent antimicrobial therapy (antibiotics, bismuth compounds) may suppress H. pylori and reduce antibody response; consider testing at least 4 weeks after completing antibiotics
- Proton pump inhibitors (PPIs) and H2-receptor antagonists do not directly affect antibody levels but may suppress bacterial growth; stop if possible 2 weeks before testing
- Immunosuppressive medications (corticosteroids, immunosuppressants) may reduce antibody production
- Additional Patient Preparation:
- No special preparation required - Patient can eat and drink normally
- Can take regular medications as usual, except as noted above regarding antimicrobials and acid suppressants
- Inform the laboratory of any recent antimicrobial therapy or acid-suppressing medications
- Blood draw can be scheduled at any convenient time - morning or afternoon collection is acceptable
- Ensure proper patient identification and labeling of specimens to prevent mix-ups

How our test process works!